AFT Pharmaceuticals Ltd. (AU:AFP) has released an update.
AFT Pharmaceuticals reports a substantial year with record revenues of $195.4 million, a 25% increase, and expanded global presence in over 70 countries, highlighted by entry into the US and Chinese markets with their Maxigesic product line. Despite robust growth and a confident outlook with plans to aim for $300 million in revenue, the company expresses disappointment over the current share price, which hovers slightly above their IPO price. The company’s financial health has improved significantly, as demonstrated by a steady growth in shareholder equity and a sound debt-to-equity ratio.
For further insights into AU:AFP stock, check out TipRanks’ Stock Analysis page.
